A5023553790- Alzheimer's disease research and treatments
- MicroRNA in disease regulation
- RNA Research and Splicing
- Mitochondrial Function and Pathology
- Dementia and Cognitive Impairment Research
- Medicinal Plants and Bioactive Compounds
- Pancreatic function and diabetes
- Biochemical effects in animals
- Adipose Tissue and Metabolism
- Circular RNAs in diseases
- Genetics and Neurodevelopmental Disorders
- Glycosylation and Glycoproteins Research
- Protein purification and stability
- Protein Tyrosine Phosphatases
- Machine Learning in Bioinformatics
- Cancer-related molecular mechanisms research
- Biochemical Acid Research Studies
- Bioinformatics and Genomic Networks
- Cholinesterase and Neurodegenerative Diseases
- Renal and related cancers
- 14-3-3 protein interactions
Université Laval
2009-2021
Centre hospitalier de l'Université Laval
2009-2020
Huazhong University of Science and Technology
2017
Centre hospitalier universitaire de Québec
2017
KU Leuven
2008-2009
Vlaams Instituut voor Biotechnologie
2006
Abstract Although APP metabolism is being intensively investigated, a large fraction of its modulators yet to be characterized. In this context, we combined two genome-wide high-content screenings assess the functional impact miRNAs and genes on signaling pathways involved. This approach highlighted involvement FERMT2 (or Kindlin-2), genetic risk factor Alzheimer’s disease (AD), as potential key modulator axon guidance, neuronal process that depends regulation metabolism. We found directly...
Old age is associated with a rise in the incidence of Alzheimer's disease (AD) but also thermoregulatory deficits. Indicative link between two, hypothermia induces tau hyperphosphorylation. The 3xTg-AD mouse model not only develops and amyloid pathologies brain metabolic Brown adipose tissue (BAT) main thermogenic driver mammals, its stimulation counteracts deficits rodents humans. We thus investigated whether BAT impedes AD neuropathology. 15-month-old mice were subjected to repeated short...
Background . The conserved noncoding microRNAs (miRNAs) that function to regulate gene expression are essential for the development and of brain heart. Changes in miRNA profiles associated with an increased risk developing neurodegenerative disorders as well heart failure. Here, hypothesis how miRNA-regulated pathways could contribute comorbid neurological cardiovascular will be discussed. Presentation occurring have impact on coexisting characteristics by (1) modulating organ function, (2)...
MicroRNAs are thought to play an important role in neurodegenerative diseases. In Alzheimer's disease and other tauopathies, the miR-132/212 cluster (encoding miR-132 miR-212) is frequently downregulated. We previously reported that miR-132, a neuron-enriched microRNA, can modulate tau alternative splicing expression vitro. Beside, recently, we could show knockout mice displayed significant memory impairments. used study effects on expression, phosphorylation, aggregation. Comparisons were...
Tau hyperphosphorylation is a main pathological hallmark of Alzheimer's disease and other tauopathies.We have previously shown that hypothermia can induce tau both in vitro vivo. In this work, we tested the hypothesis hypothermic conditions could be used to screen for kinase inhibitors. For purpose, different biological models gradual complexity such as SH-SY5Y neuronal-like cell cultures, ex vivo metabolically active brain slices, well adult non-transgenic mice. Our results show either...
ABSTRACT Although APP metabolism is being intensively investigated, a large fraction of its modulators are yet to be characterized. In this context, we combined two genome-wide high-content screenings assess the functional impact miRNAs and genes on signaling pathways involved. This approach highlighted involvement FERMT2 (or Kindlin-2), genetic risk factor Alzheimer’s disease (AD), as potential key modulator axon guidance; neuronal process that depends regulation metabolism. We found...
Quebec (Canada) is the second fastest aging society in world. Concerted efforts are thus required to reduce expected burden of Alzheimer's disease (AD). The Consortium pour l'identification précoce de la maladie d'Alzheimer - (CIMA-Q) a newly created research structure supported by Pfizer- Fonds Recherche du Santé innovation fund on AD. Investigators will develop and make available common methodological tools platforms, which vastly increase researchers' ability contribute highly innovative...
It is well established that changes in the regulation of tau expression and/or metabolism are involved development Alzheimer's disease and related tauopathies. Despite intensive investigation, however, little know about molecular mechanisms participate transcriptional post-transcriptional endogenous tau, especially neurons. We have recently shown microRNAs, particular miR-132, play an important role exon 10 alternative splicing by modulating neuronal polypyrimidine-tract binding protein 2...
It is becoming increasingly acknowledged that polymorphisms in microRNA (miRNA) target sites (PolymiRTS) may influence neurological disorders, including Parkinson's disease and frontotemporal dementia. A number of PolymiRTS the 3' untranslated region (3'UTR) AD related genes such APP, BACE1 nicastrin have been identified, some which are found exclusively patients suffering from Alzheimer's (AD). Given recent findings, we hypothesize could contribute significantly to risk for by affecting...
The discovery of small non-coding miRNAs (miRNAs) has revealed an unexpected and intriguing additional level fine-tuning the transcriptome proteome. It is now well documented that could contribute significantly to human disease. In this regard, changes in miRNA expression profiles have been Alzheimer's disease (AD) brain (and peripheral system), whereas complete removal leads neurodegeneration. MiRNAs seem participate posttranscriptional regulation APP BACE1/beta-secretase expression,...
The processing of the amyloid precursor protein (APP) has been extensively studied but its precise cellular function remains elusive. It proposed that APP intracellular domain (AICD) regulates expression several genes. However, identity target genes and mechanisms by which regulate their transcription is largely unknown. aim our work was to identify analyze how transcription. We identified analyzing gene patterns in mouse embryonic fibroblasts (MEFs) expressing or not (APP +/+ vs. APP-/-),...
Increased level of Aβ peptides in Alzheimer's disease (AD) brain, is considered a principal cause neurodegeneration. These derive from the amyloid precursor protein (APP) following sequential cleavages first by beta-site cleaving enzyme 1 (BACE1) and secondly γ-secretase, multi-protein complex, which contains presenilin-1 (PS1), nicastrin, Aph-1 Pen-2. Mutations PS1 lead to most aggressive forms early-onset familial AD. undergoes endoproteolytic cleavage an unknown order generate active...
Recent studies suggested that the APP intracellular domain (AICD) could regulate expression of several genes, but these results are still controversial.The aim our work was to identify genes be regulated by APP. To this end, we analyzed gene patterns in mouse embryonic fibroblasts (MEFs) expressing or not (APP vs. APP-/-) using Gene-chip microarrays (Affymetrix). We performed identical experiments MEFs Presenilin 1 and 2 (PS1/PS2 PS1/PS2-/-). Presenilins required for γ-secretase activity...
The main hallmark of Alzheimer's disease (AD) is the presence insoluble amyloid–beta (A–beta) deposits in brain. A–beta peptides are produced by proteolytic processing precursor protein (APP) beta– and gamma–secretases. Blocking generation inhibiting or modulating gamma–secretase APP an attractive but problematic drug target for treatment AD. Apart from side effects caused interference with Notch signaling pathway, recent results suggest that blocking would also interfere other pathways....